NI201500057A - Métodos para reducir riesgos asociados con insuficiencia cardiaca y factores asociados - Google Patents

Métodos para reducir riesgos asociados con insuficiencia cardiaca y factores asociados

Info

Publication number
NI201500057A
NI201500057A NI201500057A NI201500057A NI201500057A NI 201500057 A NI201500057 A NI 201500057A NI 201500057 A NI201500057 A NI 201500057A NI 201500057 A NI201500057 A NI 201500057A NI 201500057 A NI201500057 A NI 201500057A
Authority
NI
Nicaragua
Prior art keywords
heart failure
subject
methods
effective amount
comprise administering
Prior art date
Application number
NI201500057A
Other languages
English (en)
Spanish (es)
Inventor
D Wilson Travis
N Sabbah Hani
Original Assignee
Stealth Peptides Int Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stealth Peptides Int Inc filed Critical Stealth Peptides Int Inc
Publication of NI201500057A publication Critical patent/NI201500057A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
NI201500057A 2012-10-22 2015-04-22 Métodos para reducir riesgos asociados con insuficiencia cardiaca y factores asociados NI201500057A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261716867P 2012-10-22 2012-10-22
US201361822752P 2013-05-13 2013-05-13
US201361839750P 2013-06-26 2013-06-26
US201361839743P 2013-06-26 2013-06-26

Publications (1)

Publication Number Publication Date
NI201500057A true NI201500057A (es) 2015-07-16

Family

ID=50545459

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201500057A NI201500057A (es) 2012-10-22 2015-04-22 Métodos para reducir riesgos asociados con insuficiencia cardiaca y factores asociados

Country Status (12)

Country Link
US (4) US20150246092A1 (enExample)
EP (4) EP4397314B1 (enExample)
JP (3) JP2016503397A (enExample)
KR (1) KR20160009008A (enExample)
CN (2) CN105050613A (enExample)
AU (2) AU2013334788A1 (enExample)
BR (1) BR112015009072A2 (enExample)
CA (1) CA2889155A1 (enExample)
MX (1) MX2015005102A (enExample)
NI (1) NI201500057A (enExample)
PE (1) PE20151434A1 (enExample)
WO (1) WO2014066419A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2916884C (en) 2013-03-01 2021-02-09 Stealth Biotherapeutics Corp Methods for the treatment of mitochondrial disease
US9687519B2 (en) * 2013-03-01 2017-06-27 Stealth Biotherapeutics Corp Methods and compositions for the prevention or treatment of barth syndrome
CA2916977A1 (en) 2013-06-26 2014-12-31 Stealth Biotherapeutics Corp Methods and compositions for detecting and diagnosing diseases and conditions
WO2017180535A1 (en) 2016-04-11 2017-10-19 Carnot, Llc Chiral peptides
AU2017280348A1 (en) * 2016-06-24 2019-01-03 University Of Southern California Mentsh analogs as therapeutics for diabetes, obesity, and their associated diseases and complications
SG10201912128SA (en) 2017-02-01 2020-02-27 Univ Yale Treatment of diuretic resistance
WO2019136312A1 (en) 2018-01-05 2019-07-11 Corvidia Therapeutics, Inc. Methods for treating il-6 mediated inflammation without immunosuppression
KR102546547B1 (ko) 2018-01-11 2023-06-22 삼성전자주식회사 보행 보조 방법 및 장치
KR20220052561A (ko) 2020-10-21 2022-04-28 장영진 어류 가공물 및/또는 콩 가공물을 유효성분으로 포함하는 심부전의 예방 또는 치료용 약학 조성물
CN120329388B (zh) * 2025-04-30 2025-09-26 中日友好医院(中日友好临床医学研究所) 一种双靶点多肽及其在心衰治疗中的应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
KR20130001318A (ko) * 2002-07-19 2013-01-03 애보트 바이오테크놀로지 리미티드 ＴＮＦα 관련 질환의 치료
HUE027110T2 (en) * 2003-02-04 2016-08-29 Cornell Res Foundation Inc Use of an aromatic cationic peptide
EP1890153A1 (en) * 2006-08-16 2008-02-20 F. Hoffman-la Roche AG Cardiac troponin as an indicator of advanced coronary artery disease
EP1890154B1 (en) * 2006-08-16 2012-07-04 F. Hoffmann-La Roche AG Cardiac troponin as an indicator of advanced coronary artery disease
US20080318909A1 (en) * 2007-06-14 2008-12-25 Sparagna Genevieve C Use Of Linoleic Compounds Against Heart Failure
CN104056248A (zh) * 2008-02-26 2014-09-24 康奈尔大学 用于防止和治疗急性肾损伤的方法
JP5909182B2 (ja) * 2009-08-12 2016-04-26 コーネル ユニヴァーシティー 代謝性症候群を予防し又は治療するための方法
JP2013506696A (ja) * 2009-10-05 2013-02-28 コーネル ユニヴァーシティー 心不全の予防又は処置の方法
AU2010324739B2 (en) * 2009-11-24 2016-05-05 H. Lundbeck A/S. Antibodies to IL-6 and use thereof
AU2010339414A1 (en) * 2009-12-31 2012-07-19 Stealth Peptides International, Inc. Methods for performing a coronary artery bypass graft procedure
AU2010339410A1 (en) * 2009-12-31 2012-07-19 Stealth Peptides International, Inc. Methods for the prevention or treatment of vessel occlusion injury
EP3511012A1 (en) * 2010-02-26 2019-07-17 Cornell University Cornell Center For Technology, Enterprise & Commercialization ("CCTEC") Mitochondrial-targeted antioxidants protect against mechanical ventilation-induced diaphragm dysfunction and skeletal muscle atrophy
EP3560508A1 (en) * 2010-03-15 2019-10-30 Stealth Peptides International, Inc. Combination therapies using cyclosporine and aromatic cationic peptides
EP2879689A4 (en) * 2012-08-02 2015-12-16 Stealth Peptides Int Inc METHOD FOR THE TREATMENT OF ATHEROSCLEROSIS
EP3287172A1 (en) * 2012-12-06 2018-02-28 Stealth Peptides International, Inc. Combinations of peptide therapeutics and methods for using same
US9884085B2 (en) * 2013-06-26 2018-02-06 Stealth Biotherapeutics Corp Methods for the regulation of matrix metalloproteinase expression
CA2916977A1 (en) * 2013-06-26 2014-12-31 Stealth Biotherapeutics Corp Methods and compositions for detecting and diagnosing diseases and conditions

Also Published As

Publication number Publication date
MX2015005102A (es) 2016-02-09
EP3586862A1 (en) 2020-01-01
US20230190859A1 (en) 2023-06-22
KR20160009008A (ko) 2016-01-25
AU2013334788A1 (en) 2015-06-04
US20150246092A1 (en) 2015-09-03
WO2014066419A3 (en) 2014-06-12
BR112015009072A2 (pt) 2017-07-04
US20250255929A1 (en) 2025-08-14
EP4397314A1 (en) 2024-07-10
CN105050613A (zh) 2015-11-11
JP2016503397A (ja) 2016-02-04
JP2018109012A (ja) 2018-07-12
AU2018206766A1 (en) 2018-08-09
EP4397314B1 (en) 2025-12-03
EP4005582A1 (en) 2022-06-01
EP2908839A4 (en) 2016-06-15
US20200360462A1 (en) 2020-11-19
WO2014066419A2 (en) 2014-05-01
CA2889155A1 (en) 2014-05-01
EP2908839A2 (en) 2015-08-26
CN110193077A (zh) 2019-09-03
JP2019194193A (ja) 2019-11-07
PE20151434A1 (es) 2015-10-16
EP3586862B1 (en) 2021-12-08
HK1213799A1 (en) 2016-07-15
EP2908839B1 (en) 2019-08-21

Similar Documents

Publication Publication Date Title
NI201500057A (es) Métodos para reducir riesgos asociados con insuficiencia cardiaca y factores asociados
UK Chronic heart failure in adults: diagnosis and management
UY39119A (es) Proteínas de fusión para tratar trastornos metabólicos
ES2694667T3 (es) Método para producir oxalato oxidasas que tienen actividad óptica cerca de pH fisiológico y uso de tales oxalato oxidasas recombinantes en el tratamiento de enfermedades relacionadas con oxalato
CY1126074T1 (el) Περιοχες gla ως παραγοντες στοχευσης
CR20160097A (es) Construcciones del factor de diferenciación de crecimiento 15 (gdf-15)
MX2015013948A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
MX2019010735A (es) Sistemas y metodos para la produccion dirigida de una proteina terapeutica dentro de una celula objetivo.
MX2016004822A (es) Modelos de cancer y metodos asociados.
NZ630009A (en) Angiogenesis using placental stem cells
AR092456A1 (es) Proteinas de fusion para el tratamiento de un sindrome metabolico
AR080643A1 (es) Identificacion de la mutacion de lkb1 como un biomarcador predictivo para la sensibilidad a inhibidores de la tor quinasa
NI201400111A (es) Tratamiento del cáncer con inhibidores tor cinasa
AR095555A1 (es) Uso terapéutico de los anticuerpos dirigidos al factor de crecimiento de hepatocitos (hgf)
MX2017005186A (es) Celulas madre neurales estables que comprenden un polinucleótido exógeno que codifica un factor de crecimiento y métodos de uso de las mismas.
TW201614069A (en) Inhibitors of MYH7B and uses thereof
IN2014DN03049A (enExample)
CO2023000307A2 (es) Polipéptidos de mybpc3 y usos de los mismos
CO6430497A2 (es) Metodo o sistema que usa biomarcadores para el seguimiento de un tratamiento
EA201890623A1 (ru) Рациональная комбинированная терапия для лечения рака
BR112016028561A2 (pt) composição, forma de dosagem, e, métodos para reduzir o risco para mortalidade em um indivíduo, o risco para uma doença ou condição em um indivíduo, triglicerídeos em um sangue de indivíduo, a frequência cardíaca em repouso de um indivíduo, o colesterol de lipoproteína de densidade não alta em um indivíduo, o colesterol total em um indivíduo, a apolipoproteína b em um sangue de indivíduo, pressão sanguínea sistólica em um indivíduo e a pressão sanguínea diastólica em um indivíduo, para prolongar a vida de um indivíduo, para tratar hipertrigliceridemia em um indivíduo e para aumentar um índice de ômega-3 em células vermelhas do sangue de um indivíduo.
MX2021011598A (es) Uso de mir101 o mir128 en el tratamiento de trastornos convulsivos.
CO2017001899A2 (es) Tratamiento del cáncer con el inhibidor de la alfa-amilasa en los animales de compañía
PH12015502037B1 (en) Activating adiponectin by casein hydrolysate
JOP20220121A1 (ar) خلية ناقلة مساعدة اصطناعية تحتوي على ny-eso-1- للاستخدام في علاج سرطان